Analysts don’t see higher bid for Cephalon
May 02, 2011 at 16:37 PM EDT
Cephalon Inc. investors shouldn’t hold their breath for a bid to emerge that tops Teva Pharmaceutical Industries Ltd.’s $81.50-a-share offer, analysts say.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.